Spyre Therapeutics (SYRE) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$11.2 million.
- Spyre Therapeutics' Net Income towards Common Stockholders rose 8379.93% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 3068.05%. This contributed to the annual value of -$208.0 million for FY2024, which is 3859.97% up from last year.
- Latest data reveals that Spyre Therapeutics reported Net Income towards Common Stockholders of -$11.2 million as of Q3 2025, which was up 8379.93% from -$36.7 million recorded in Q2 2025.
- Spyre Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$6.8 million during Q2 2021, with a 5-year trough of -$217.1 million in Q2 2023.
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$24.4 million (2022), whereas its average is -$41.5 million.
- Per our database at Business Quant, Spyre Therapeutics' Net Income towards Common Stockholders tumbled by 87245.44% in 2023 and then surged by 8379.93% in 2025.
- Over the past 5 years, Spyre Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$20.4 million in 2021, then grew by 7.94% to -$18.8 million in 2022, then tumbled by 235.67% to -$63.2 million in 2023, then increased by 10.9% to -$56.3 million in 2024, then soared by 80.14% to -$11.2 million in 2025.
- Its last three reported values are -$11.2 million in Q3 2025, -$36.7 million for Q2 2025, and -$44.8 million during Q1 2025.